1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Development of devices, diagnostic technologies, or digital health tools for treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers - Topic is sponsored by National Cancer Institute (NCI) SBIR. This SBIR solicitation encourages small businesses to propose innovative technologies for the prevention, diagnosis, treatment, and care of pediatric or rare cancer patients.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
#### Looking for contract opportunity help? * **Contract Opportunity Type:**Presolicitation (Original) * **Original Published Date:**Mar 28, 2025 06:51 am EDT * **Original Response Date:**Apr 13, 2025 05:00 pm EDT * **Inactive Policy:**15 days after response date * **Original Inactive Date:**Apr 28, 2025 * **Original Set Aside:**Total Small Business Set-Aside (FAR 19.
5) * **Product Service Code:** AN12 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH * 54171 - Research and Development in the Physical, Engineering, and Life Sciences * **Place of Performance:** The National Cancer Institute (NCI) is soliciting proposals from small business concerns to perform key activities to demonstrate technical feasibility and proof-of-concept for the development of highly innovative and potentially transformative technologies in the following areas: * **Topic 1:** Development of therapeutic or preventative technologies for treatment or prevention of Pediatric Cancers and/or Rare Cancers.
* **Topic 2:** Development of devices, diagnostic technologies, or digital health tools for treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers. For this solicitation, rare cancers with a 5-year survival rate of less than 50% are encouraged and rare cancers include all the cancers listed by the NIH Genetics and Rare Diseases Information Center (https://rarediseases. info.
nih. gov/diseases/diseases-bycategory/1/rare-cancers). For more information regarding 5-year cancer survival rates, see the NCI Surveillance, Epidemiology, and End Results Program (SEER) database at https://seer.
cancer. gov/. Preliminary data is not required.
However, the proposal must have a sound scientific premise either based on the offeror’s own research or literature evidence. Proposals shall both identify an anticipated product to be developed and clearly lay out the anticipated development path. Proposals must clearly identify the clinical problem and cancer type(s) along with adequate justification.
In addition, the offerors should propose experiments to obtain initial de-risking and proof-of-concept data. Awards will also include requirements to enhance entrepreneurial skills, to develop or refine a business model, and commercialization plan. This Concept Award solicitation is intended to serve as a pipeline for the federal Small Business Innovation Research (SBIR) program.
This is a total small business set-aside solicitation, and only proposals from eligible small businesses will be considered for award. This size standard is established by law for the SBIR program, regardless of the NAICS Code assigned. To be eligible as a small business, the offeror may have no more than 500 employees, including the employees of its Affiliates (see 13 C.
F. R. § 121.
702). For other requirements, see the SBA’s SBIR/STTR Policy Directive: https://www. sbir.
gov/sites/default/files/SBA%20SBIR_STTR_POLICY_DIRECTIVE_May2023. pdf. The solicitation for the NCI SBIR Innovative Concept Award Program is anticipated to be available on or around April 14, 2025, and the expected closing date for receipt of proposals is September 26, 2025.
There will be an interim white paper submission deadline in June to allow time for the NCI to provide feedback on whether the proposal within the scope of this solicitation. **NOTE – SBIR / STTR GRANT OPPORTUNITIES** Other SBIR and STTR contract and grant opportunities are also available. Companies are encouraged to visit: https://seed.
nih. gov/small-business-funding/find-funding. For general information regarding the NCI SBIR Program, please refer to: https://sbir.
cancer. gov/. * OFFICE OF ACQUISITIONS 31Center Dr. 11A35P * **May 14, 2025 11:17 am EDT**Solicitation (Original) * **Apr 28, 2025 11:55 pm EDT**Presolicitation (Original) * **Apr 15, 2025 08:57 am EDT**Solicitation (Original)
According to the current listing, eligibility includes: Small businesses with innovative ideas focused on detection, prevention, and treatment of pediatric or rare cancers. Confirm the full requirements in the official notice before applying.
Development of devices, diagnostic technologies, or digital health tools for treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers - Topic is funded by National Cancer Institute (NCI) SBIR. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
On September 2, 2026, SBA published an updated commercialization benchmark: firms with more than 25 Phase II awards in five years must derive at least 33 percent of total revenue from non-SBIR sources in FY2027, and 50 percent from FY2028 onward. It takes effect November 15, 2026. Because the measurement window looks backward three completed fiscal years, the first test is already decided — and the second is two-thirds decided. Here is the arithmetic, the history, and what firms near the line should do.
Read articleOSW26BZ06-DV033 pays up to $1,500,000 over 24 months for agentic AI cognitive radar. But TS/SCI is gating, polygraphs must finish in 90 days, foreign nationals are barred even from unclassified work, and your feasibility evidence cannot come from prior SBIR funding. Here is how to read a security-gated SBIR before the October 21 deadline.
Read articleNSF's $20 million Commercialization Readiness Pilot, announced September 14, 2026 and led by UCF's National Commercialization and Translation Institute, will give six to eight Phase II and IIB deep-tech firms milestone awards of $1 million to $3.75 million. Roughly one in ten NSF Phase IIB alumni will get a seat. Here is how the selection logic actually works.
Read article